Dr. Sharman on 5-Year Data From the Elevate CLL TN Trial in CLL

Jeff Sharman, MD, director of research, the Willamette Valley Cancer Institute, medical director of hematology research, The US Oncology Network, discusses 5-year follow-up data from the phase 3 Elevate CLL TN trial (NCT02475681) in treatment-naïve patients with chronic lymphocytic leukemia (CLL).

The Elevate CLL TN study investigated the efficacy of acalabrutinib (Calquence) monotherapy vs acalabrutinib plus obinutuzumab (Gazyva) vs obinutuzumab plus chlorambucil in patients with previously untreated CLL. A 5-year updated analysis was performed to determine the long-term benefits of the 3 regimens studied.

Initial findings from the Elevate CLL TN trial showed that the acalabrutinib-containing arms showed superiority over the obinutuzumab plus chlorambucil arm in terms of efficacy and safety, Sharman says. At 5 years, the acalabrutinib arms continue to demonstrate a progression-free survival benefit vs obinutuzumab plus chlorambucil, Sharman explains.

These follow-up data also show an overall survival (OS) benefit for acalabrutinib plus obinutuzumab vs obinutuzumab plus chlorambucil, Sharman notes. Acalabrutinib monotherapy also seems promising, but has not yet shown an OS benefit, Sharman concludes.